- Entheon Biomedical Corp. (ENBI) has entered into an agreement with Psychedelics Today, LLC to drive awareness for the Psychedelics Genetic Test Kit
- The test kit identifies specific DNA to gauge the risk and potential of adverse reactions toward hallucinogenic drugs
- The kit is developed and commercialized by Entheon’s subsidiary HaluGen Life Sciences Inc. and is available for sale both in the US and Canada
- The test kit was recently expanded to include a key distribution biomarker, the CYP2D6 gene
- Entheon Biomedical Corp. (ENBI) is down 7.41 per cent and is trading at $0.25 per share as of 1:29 p.m. EST
Entheon Biomedical Corp. (ENBI) has entered into an agreement with Psychedelics Today, LLC to drive awareness for the Psychedelics Genetic Test Kit.
The test kit identifies specific DNA to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
The kit is developed and commercialized by Entheon’s subsidiary HaluGen Life Sciences Inc. and is available for sale both in the US and Canada.
The agreement with Psychedelics Today can expand access to and visibility for HaluGen’s Psychedelics Genetic Test Kit.
The test provides users with personalized reports and insight into the short and long-term potential of psychedelic-induced risks, such as psychosis.
The test kit was recently expanded to include a key distribution biomarker, the CYP2D6 gene.
The CYP2D6 ‘poor metabolizer’ gene mutation influences the metabolism of LSD, MDMA and ayahuasca.
The mutation can cause individuals to metabolize these hallucinogenic drugs up to two times slower than normal.
Poor metabolizers can also experience an increased duration, intensity of effect and adverse drug reactions.
The test kit also includes other relevant distribution, drug effects and mental health risk biomarkers.
For example, the HTR2A gene can impact response to serotonin, which is the primary mechanism of action for psychedelics.
The CYP2B6 gene can decrease the metabolism of ketamine for people who carry this gene variant.
Additionally, C4A, NRG1 and DISC1 genes can influence mental health risks.
Entheon Biomedical Corp. (ENBI) is down 7.41 per cent and is trading at $0.25 per share as of 1:29 p.m. EST.